

GENERAL INFORMATION

VENUE

OBA (Openbare Bibliotheek Amsterdam)
Amsterdam Public Library
Oosterdokskade 143
1011 DL Amsterdam

REGISTRATION

Registration fee: € 50,--
(includes lunch, coffee & tea)
Registration on-line: www.epgs.nl

ACCREDITATION

Accreditation has been requested.
All participants will receive a certificate of attendance.

INFORMATION

For further information please contact:

EPGS-AMC
Meibergdreef 9
1105 AZ Amsterdam

Tel: 020-566 3926/6468
E-mail: epgs@amc.nl

EDUCATIONAL GRANTS BY



Therapeutic Drug Monitoring of Biologics: Progress in Chronic Inflammatory Diseases

Openbare Bibliotheek Amsterdam (OBA)
the Amsterdam Public Library
December 9, 2016

Openbare Bibliotheek Amsterdam



INTRODUCTION

Therapeutic drug monitoring of biologic medicines is a novel but pivotal concept in inflammatory diseases. New data show a relationship between the dose of these therapeutic monoclonal antibodies, their concentration in serum and tissue (pharmacokinetics, PK) and the biologic and clinical effect they exert (pharmacodynamics, PD). Sufficient target engagement appears to be of paramount importance, whereas the immunogenicity of the monoclonal antibodies is an additional confounding factor that needs to be taken into account.

We wish to share all novel and clinically relevant information in this rapidly growing field with clinicians who are active in rheumatology, dermatology and gastroenterology and with pharmacists/clinical pharmacologists with a special interest in PK-PD of biologics.

Sanquin and the Academic Medical Center in Amsterdam jointly invited a number of leading investigators in this field, ensuring highly informative and challenging lectures. There will be ample networking opportunities during the entire meeting.

We look forward to welcoming you in the public library in the very heart of Amsterdam, The Netherlands.

The steering committee

Gertjan Wolbink, Annick de Vries, Phyllis Spuls, Ron Mathôt, Geert D’Haens

FACULTY

- Prof. Shomron Ben-Horin, Tel Aviv University, Ramat Aviv, Israel
- Prof. Ann Gils, University of Leuven, Leuven, Belgium
- Prof. João Gonçalves, University of Lisbon, Lisbon, Portugal
- Prof. Geert D’Haens, Academic Medical Center, The Netherlands
- Prof. Pekka Kurki, EMA, Helsinki, Finland
- Prof. Jo Lambert, University Hospital Ghent, Ghent, Belgium
- Prof. Marcel Levi, Dean of the Academic Medical Center, The Netherlands
- Prof. Ron Mathôt, Academic Medical Center, The Netherlands
- Dr. Diane Mould, Projections Research Inc., Phoenix, U.S.A.
- Prof. Denis Mulleman, Université François Rabbelais, Tours, France
- Dr. Theo Rispens, Sanquin, Amsterdam, The Netherlands
- Prof. Catherine Smith, St John’s Institute of Dermatology, London, U.K.
- Prof. Phyllis Spuls, Academic Medical Center, The Netherlands
- Prof. Ronald van Vollenhoven, Academic Medical Center, The Netherlands
- Dr. Annick de Vries, Sanquin, Amsterdam, The Netherlands
- Dr. Gertjan Wolbink, Sanquin and Reade, Amsterdam, The Netherlands

PROGRAM

- 09.30-09.45 INTRODUCTION
Hospital perspective on costs of biologicals and how to use them properly
Marcel Levi
- 09.45-11.15 SESSION 1: All you need to know about therapeutic antibodies
Chair: Gertjan Wolbink
- 09.45-10.15 Biologics in Rheumatology: Past, Present and Future
Ronald van Vollenhoven
- 10.15-10.45 Why are biologicals immunogenic and how can you quantify?
Theo Rispens
- 10.45-11.15 Dose-finding and PK/PD optimization with biologicals
Diane Mould
- 11.15-11.30 COFFEE BREAK
- 11.30-13.00 SESSION 2: PK/PD issues on the Horizon
Chair: Diane Mould
- 11.30-12.00 How the regulators look at biological and immunogenicity
Pekka Kurki
- 12.00-12.30 PK/PD issues with biosimilars
João Gonçalves
- 12.30-13.00 Implementation of TDM: Crossing the last hurdles
Ann Gils
- 13.00-13.45 LUNCH

- 13.45-15.15 SESSION 3: Clinical relevance of TDM
Chair: Ronald van Vollenhoven, Phyllis Spuls
- 13.45-14.05 Modeling for biologic dosing and dashboard systems
Ron Mathôt
- 14.05-14.25 TDM in psoriatic patients: sense or nonsense?
Jo Lambert
- 14.25-14.45 Prospective TDM data in IBD: what are we missing?
Geert D’Haens
- 14.45-15.05 Tapering biologics: how relevant is the PK?
Gertjan Wolbink
- 15.05-15.30 Panel Forum
- 15.30-16.00 TEA BREAK
- 16.00-17.15 Session 4: Clinical management of immunogenicity
Chair: Geert D’Haens, Ann Gils
- 16.00-16.20 Prevention and management of antidrug antibodies. The value of combination treatment in IBD
Shomron Ben-Horin
- 16.20-16.40 Optimising outcomes using therapeutic drug level monitoring for biologic therapy in psoriasis
Catherine Smith
- 16.40-17.00 Methotrexate in combination with biologics in rheumatic diseases
Denis Mulleman
- 17.00-17.15 Q&A